Global Difficile-Associated Diarrhea Treatment Market, By Symptoms (Mild to Moderate, Severe Infection), Treatment (Antibiotics, Vancomycin and Metronidazole), Type (Narrow Spectrum Antibiotics, Broad Spectrum Antibiotics), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Difficile-Associated Diarrhea Market Analysis and Size
Clostridium difficile infection usually affects older adults. According to the Centers for Disease Control and Prevention (CDC), 2015, clostridium difficile infection is the most common healthcare-associated infection. Regular antibiotic medication is also responsible for clostridium difficile infection, as antibiotics kill normal flora and allow for the multiplication of C. difficile bacteria. The infection has significantly increased in recent years as many new strains have appeared and antimicrobial resistance has increased. It is one of the closely associated causes of antibiotic-related diarrhea, with symptoms such as pseudomembranous colitis, mild, self-limiting diarrhea to severe diarrhea, and life-threatening fulminant colitis, which typically results in death.
Data Bridge Market Research analyses a growth rate in the global difficile-associated diarrhea market in the forecast period 2023-2030. The expected CAGR of the global difficile-associated diarrhea market tends to be around 12.00% in the mentioned forecast period. The market was valued at USD 2.9 billion in 2022 and would grow to USD 7.18 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Difficile-Associated Diarrhea Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Symptoms (Mild to Moderate, Severe Infection), Treatment (Antibiotics, Vancomycin and Metronidazole), Type (Narrow Spectrum Antibiotics, Broad Spectrum Antibiotics), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
TECHLAB, Inc. (U.S.)., F. Hoffmann-La Roche AG (Switzerland), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Baxter (U.S.)., Trinity Biotech (Ireland), Baxter (U.S.), Sanofi (France)., Summit Therapeutics, Inc (U.S.), AstraZeneca (U.K.), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (U.K.), Astellas Pharma Inc. (Japan), Amorphex Therapeutics Holdings, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Primary clostridioides difficile is a bacterial infection that can cause symptoms varying from diarrhea to life-threatening colon inflammation. It has also emerged as a cause of community-associated diarrhea, ensuing in an increased incidence of community-associated infection. Clinical illness ranges in severity from mild diarrhea to colitis and death. It is one of the closely related causes of antibiotic-related diarrhea, with symptoms such as mild, self-limiting diarrhea to severe diarrhea, pseudomembranous colitis, and life-threatening fulminant colitis that usually results in death.
Global Difficile-Associated Diarrhea Market Dynamics
Drivers
- Rising Adoption of Antibiotics
Clostridium difficile infection is primarily associated with long-term antibiotic use. Rising antibiotic consumption changes the colon bacteria, allowing Clostridium difficile bacteria to grow. Antibiotics such as cephalosporins, clindamycin, and quinolones are more likely to cause Clostridium difficile infection (CDI). The growing use of these antibiotics is directly increasing the incidence of clostridium difficile infection which is most likely to boost the demand for its treatments. Thus, the increasing consumption of antibiotics acts as a major driver of growth in the global primary clostridium difficile infection treatment market.
- Growing Prevalence of Clostridium Difficile Infection
The occurrence of clostridium difficile infection has been witnessing an increase in the recent past because of the clostridium difficile infection recurrence and antibiotic resistance. As per the Centers for Disease Control and Prevention (CDC), 2015, about half a million people in the U.S. suffer from clostridium difficile infection annually. Moreover, according to National Center for Biotechnology Information (NCBI) records, around 37,900 patients suffered from clostridium difficile infection in Canada in 2012. Thus, it boosts market growth.
Opportunities
- Rising Drug Development Activities
Higher drug development activities for developing and launching several new drugs are projected to create market opportunities for growth by providing doctors with an alternative treatment option. Presently, there are no alternative therapies other than antibiotics, and the only other option available is surgery, fecal microbiota transplant, and probiotics in case of recurrent clostridium difficile infection. Though, manufacturers such as Rebiotix, Inc., Synthetic Biologics, Inc., Da Volterra, Crestovo LLC, and Immuron Ltd. have various microbiome therapeutics in the pipeline for clostridium difficile infection indication. Therefore, increased drug development activities for developing novel drugs for better treatment and prevention are anticipated to create market growth shortly.
- Increasing Demand for Retail Pharmacies
The increasing rate of these infectious therapeutics being delivered through retail pharmacies and the rise in the number of retail pharmacies in highly developed countries create many opportunities for market growth. In addition, patients elect retail pharmacies to purchase drugs, as these are easily available.
Restraints/Challenges
- Lack of Skilled Professionals
The lack of trained healthcare professionals who cannot treat the patients with appropriate treatments could limit the growth of the global difficile-associated diarrhea market during a forecast period.
- High Cost For Drug Development
The current treatment options for CDIs are limited to antibiotics, and various pharmaceutical companies are presently focusing on developing non-antibiotic alternatives. Developing a new class of drugs will offer many growth opportunities for key market players, but it will also require major investments in R&D activities of novel therapies. The significantly high investment requirements may act as an obstacle to market growth.
This global difficile-associated diarrhea market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global difficile-associated diarrhea market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Difficile-Associated Diarrhea Market Scope
The global difficile-associated diarrhea market is segmented on the basis of symptoms, type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Symptoms
- Mild to Moderate Infection
- Severe Infection
Treatment
- Antibiotics
- Vancomycin
- Metronidazole
Type
- Narrow Spectrum Antibiotics
- Broad Spectrum Antibiotics
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Difficile-Associated Diarrhea Market Regional Analysis/Insights
The global difficile-associated diarrhea market is analysed and market size insights and trends are provided by treatment, symptoms, type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global difficile-associated diarrhea market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing positive growth for the global difficile-associated diarrhea market throughout the forecasted period due to continuous visiting of hospitals owing to increased susceptibility of infections in the region.
Asia-Pacific dominates the market due to the increased prevalence of clostridioides difficile infection and increasing population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Difficile-Associated Diarrhea Market Share Analysis
The global difficile-associated diarrhea market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global difficile-associated diarrhea market.
Key players operating in the global difficile-associated diarrhea market include:
- TECHLAB, Inc (U.S.).
- F. Hoffmann-La Roche AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Baxter (U.S.).
- Trinity Biotech (Ireland)
- Baxter (U.S.)
- Sanofi (France)
- Summit Therapeutics, Inc (U.S.)
- AstraZeneca (U.K.)
- Novartis AG (Switzerland)
- Hikma Pharmaceuticals plc (U.K.)
- Astellas Pharma Inc. (Japan)
- Amorphex Therapeutics Holdings, Inc (U.S.)
Research Methodology: Global Difficile-Associated Diarrhea Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
SKU-